Case ReportsTreating Schizophrenia With the Diuretic Bumetanide A Case ReportLemonnier, Eric MD; Lazartigues, Alain MD, PhD; Ben-Ari, Yehezkel PhDAuthor Information *Centre Expert Autisme Limousin, Limoges; and †Neurochlore c/o Inmed, INSERM U901, Marseilles, France. Address correspondence and reprint requests to Eric Lemonnier, MD, Centre Expert Autisme Limousin, CHU Limoges, Hopital Le Cluzeau, 23 Avenue Dominique Larrey, 87000 Limoges, France; E-mail: firstname.lastname@example.org; Yehezkel Ben-Ari, PhD, Neurochlore c/o Inmed, INSERM U901, 163 Route de Luminy, Marseilles 13273, France; E-mail: email@example.com Conflicts of Interest and Source of Funding: E.L and Y.B.-A. are founders of Neurochlore a company devoted to develop novel treatments for autism. Clinical Neuropharmacology: March/April 2016 - Volume 39 - Issue 2 - p 115-117 doi: 10.1097/WNF.0000000000000136 Buy Metrics Abstract Administration of the diuretic and NKCC1 chloride cotransporter antagonist bumetanide reduces the severity of autism spectrum disorders in children, and this effect is mediated by a reduction of the elevated intracellular chloride concentrations and a reinforcement of GABAergic inhibition (Lemonnier et al Transl Psychiatry. 2012;2:e202; Tyzio et al Science. 2014;343:675–679). Here, we report that this treatment also reduces the severity of symptoms in an adolescent with schizophrenia. Long-term treatment reduced hallucinations significantly, suggesting that this treatment may also be useful to treat schizophrenia. Further clinical trials and experimental studies are warranted to test this hypothesis. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.